Quazar

QUASAR Therapeutics is a Munich-based biotechnology startup focused on developing a new class of regulators for the complement system to treat life-threatening diseases. The company's proprietary technology leverages human complement proteins to create novel therapeutic agents that aim to overcome the limitations of current complement inhibitors. By targeting the innate immune system's complement cascade, QUASAR seeks to address unmet medical needs in patients who continue to suffer from symptoms despite existing treatments. Currently incubated at the MAxL (Munich Accelerator for Life Sciences), the company is advancing its lead candidate through in vivo proof-of-principle studies.